


# PRESCRIBING GUIDELINES FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS

## Complete baseline ADHD assessment & offer medication to adults if:

- Their ADHD symptoms are still causing significant impairment in at least one domain after environmental modifications have been implemented and reviewed

For pre-treatment assessment & ongoing monitoring click [here](#) & print patient information leaflets from [Choice and medication](#) website



## PRESCRIBING ADVICE FOR ALL PATIENTS

Review diagnosis and co-morbidities if expected response to treatment is not observed, especially when changing type of drug treatment (stimulant to non-stimulant, and vice versa). Seek second opinion or refer to tertiary services any adult unresponsive to one or more stimulants or one non-stimulant

Consider shared care (where this has been agreed) once patient is clinically stable.

Consider adjunctive therapies only with advice from tertiary service: e.g. atypical antipsychotics (co-existing pervasive aggression, rages or irritability) or guanfacine (both unlicensed)<sup>1</sup>

1. For advice on appropriate dosages or conversion, please contact a member of the Trust pharmacy team
2. Capsules may be opened and the capsule contents sprinkled onto a small amount (tablespoon) of apple sauce or yoghurt and given immediately, and not stored for future use.

Title	Prescribing Guidelines for ADHD in Adults		
Approved by	Drug & Therapeutics Committee	Date of Approval	24 <sup>th</sup> May 2018
Protocol Number	PHARM-0091-v1	Date of Review	31 <sup>st</sup> May 2021

**PRESCRIBING GUIDELINES FOR  
ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS**

**AVAILABLE METHYLPHENIDATE MODIFIED-RELEASE PREPARATIONS**

See guidance [here](#) for more information on relative pharmacokinetics

Brand	Available strengths	Description	Release profile	NHS indicative price (30 units)
<b>Preparations with 22% immediate-release component and 78% extended-release components</b>				
Delmosart tablets	18mg	Yellow capsule shape tablet	Immediate-release component gives a maximum plasma concentration after 1-2 hours; extended-release component gives a second peak after 6-8 hours. Duration of action up to 12 hours.	£15.59
	27mg	Grey capsule shape tablet		£18.41
	36mg	White capsule shape tablet		£21.23
	54mg	Red capsule shape tablet		£36.81
Xenidate XL tablets	18mg	Yellow round tablet		£15.57
	27mg	Yellow oblong tablet		£18.39
	36mg	White oblong tablet		£21.21
	54mg	Red oblong tablet		£36.79
Xaggitin XL tablets	18mg	Yellow capsule shape tablet		£15.58
	27mg	Grey capsule shape tablet		£18.40
	36mg	White capsule shape tablet		£21.22
	54mg	Red/brown capsule shape tablet		£36.80
Concerta XL tablets	18mg	Yellow capsule shape tablet		£31.19
	27mg	Grey capsule shape tablet		£36.81
	36mg	White capsule shape tablet		£42.45
	54mg	Red capsule shape tablet		£73.62
Matoride XL tablets	18mg	Yellow round tablet	£15.58	
	36mg	White round tablet	£21.22	
	54mg	Pink round tablet	£36.80	
<b>Preparations with 30% immediate-release component and 70% extended-release component</b>				
Equasym XL capsules <sup>2</sup>	10mg	Dark green opaque capsule	Immediate-release component gives a maximum plasma concentration after 1.5 hours; extended-release component gives a second peak after 6 hours. Duration of action up to 8 hours.	£25.00
	20mg	Blue opaque capsule		£30.00
	30mg	Reddish brown opaque capsule		£35.00
<b>Preparations with 50% immediate-release component and 50% extended-release component</b>				
Medikinet XL capsules <sup>2</sup> <i>Take with or after breakfast</i>	5mg	White capsule	Immediate-release component gives a rapid peak plasma concentration; extended-release component gives a second peak after 3-4 hours. Duration of action up to 8 hours.	£24.04
	10mg	Lilac/ white capsule		£24.04
	20mg	Lilac capsule		£28.86
	30mg	Purple/ light grey capsule		£33.66
	40mg	Purple/ grey capsule		£57.72
	50mg	Violet/dark violet capsule		£62.52
	60mg	Dark violet capsule		£67.32

Title	Prescribing Guidelines for ADHD in Adults		
Approved by	Drug & Therapeutics Committee	Date of Approval	24 <sup>th</sup> May 2018
Protocol Number	PHARM-0091-v1	Date of Review	31 <sup>st</sup> May 2021